Investment Research Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Investment Research Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475K	Buy	+956	New	+$424K	0.16%	146

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Investment Research Partners's VRTX Position: Q2 2026 in Review

Investment Research Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 956 shares worth $475K. The stake represents 0.16% of the portfolio and ranks #146 among its holdings.

1,296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Investment Research Partners held 956 shares of Vertex Pharmaceuticals worth $475K as of Q2 2026.
Vertex Pharmaceuticals was a new Investment Research Partners position in Q2 2026.
Vertex Pharmaceuticals made up 0.16% of Investment Research Partners's portfolio in Q2 2026, its #146 holding.
1,296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Investment Research Partners's 13F filing for Q2 2026, filed 4 Aug 2026.